Compound synthesis and formulation The different GLP1-based multi-agonists employed in the study, including GLP1/E, GLP1/GIP dual agonist, and GLP1/GIP/glucagon triagonist, as well as the GLP1 mono-agonist, were synthesized, purified and characterized as extensively reported elsewhere 33,34,35,74
however, the incidence of acute gallbladder disease was greater in Wegovy patients than in placebo patients, even after accounting for the degree of weight loss
The active pharmaceutical ingredients themselves are FDA-recognized
October 2023
However, based on the studies conducted so far, the side effects appear similar to other weight loss injections, but potentially more intense due to its triple action